Individualized, Heterologous Chimpanzee Adenovirus and Self-Amplifying mRNA Neoantigen Vaccine for Advanced Metastatic Solid Tumors: Phase I Trial Interim Results

Safety, tolerability, and recommended Phase II dose of an individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA-based neoantigen vaccine in combination with nivolumab and ipilimumab were assessed as primary endpoints in an ongoing Phase I/II study in patients with advanced metastatic solid tumors.